LYTIR

Company · MDGL

Madrigal Pharmaceuticals, Inc.

Name as listed on its exchange; filed with the SEC as MADRIGAL PHARMACEUTICALS, INC.

Nasdaq's symbol directory lists MDGL on Nasdaq as “Madrigal Pharmaceuticals, Inc. - Common Stock”.

In the 12 months to Nov 19, 2026: insiders bought on 2 occasions ($35.0M); insiders sold on 5 occasions ($8.4M); 4 planned-sale notices; 3 filings by holders of 5% or more; 1 company report (Form 8-K, since May 26, 2026).

All insider filings at the SEC · Appeared in No. 8, No. 7, No. 6

Insider purchases and sales, by month (last 12 months)Insider purchases: $35.0M in total; Insider sales: $8.4M in total.Jul: Insider sales $1.4MAug: Insider sales $342KSep: Insider sales $6.2MNov: Insider purchases $35.0MNov: Insider sales $431KDecJanFebMarAprMayJunJulAugSepOctNov$35.0M$6.2M
Insider purchases above the line: $35.0MInsider sales below: $8.4M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. BAKER BROS. ADVISORS LP bought on 2 days latest Nov 6, 2026 bought $35.0M
  2. Sibold William John, President and CEO sold on 3 days 2 of them under a 10b5-1 plan latest Sep 11, 2026 sold $7.6M
  3. Kelley Shannon T, General Counsel sold on 2 days 1 of them under a 10b5-1 plan latest Nov 6, 2026 sold $773K
Every trade (7)
  1. BUYBAKER BROS. ADVISORS LP bought Nov 6, 2026 76,140 shares 3 legs combined filing $29.3M
  2. SELLKelley Shannon T, General Counsel sold Nov 6, 2026 1,077 shares 10b5-1 plan (scheduled) filing $431K
  3. BUYBAKER BROS. ADVISORS LP bought Nov 4, 2026 15,666 shares 2 legs combined filing $5.8M
  4. SELLSibold William John, President and CEO sold Sep 11, 2026 5,221 shares 10 legs combined 10b5-1 plan (scheduled) filing $2.8M
  5. SELLSibold William John, President and CEO sold Sep 9, 2026 6,362 shares 14 legs combined 10b5-1 plan (scheduled) filing $3.4M
  6. SELLKelley Shannon T, General Counsel sold Aug 17, 2026 664 shares filing $342K
  7. SELLSibold William John, President and CEO sold Jul 20, 2026 2,500 shares 10 legs combined filing $1.4M

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. SHANNON KELLEY filed Nov 6, 2026 Officer 1,077 shares planned sale date 11/06/2026 filing $431K
  2. PAUL FRIEDMAN filed Sep 28, 2026 Director 50,000 shares planned sale date 09/28/2026 filing $25.8M
  3. WILLIAM SIBOLD filed Sep 11, 2026 Director 5,221 shares planned sale date 09/11/2026 filing $2.8M
  4. William John Sibold filed Sep 9, 2026 Officer and Director 6,362 shares planned sale date 09/09/2026 filing $3.4M

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. RTW Investments, LP filed Nov 16, 2026 Schedule 13G/A passive filing 1.4%
  2. Baker Bros. Advisors LP filed Nov 6, 2026 Schedule 13D/A may seek influence 2,330,144 shares filing 9.99%
  3. BlackRock, Inc. filed Jul 29, 2026 Schedule 13G/A passive 1,067,346 shares filing 4.6%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Nov 3, 2026

Lobbying · Senate LDA reports

Lobbying filed

13 quarterly lobbying reports for 2026 naming Madrigal Pharmaceuticals, Inc. as the client: 3 filed by the company itself, 10 by outside firms it hired. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.

  1. The company itself Q3 2026 filing $350K
  2. BALLARD PARTNERS Q3 2026 filing $120K
  3. CAPITOL COUNSEL LLC Q3 2026 filing $60K
  4. CROSSROADS STRATEGIES, LLC Q3 2026 filing $50K
  5. The company itself Q2 2026 filing $380K
  6. BALLARD PARTNERS Q2 2026 filing $120K
  7. CAPITOL COUNSEL LLC Q2 2026 filing $60K
  8. CROSSROADS STRATEGIES, LLC Q2 2026 filing $50K
  9. The company itself Q1 2026 filing $380K
  10. BALLARD PARTNERS Q1 2026 filing $120K
  11. CAPITOL COUNSEL LLC Q1 2026 filing $60K
  12. CROSSROADS STRATEGIES, LLC Q1 2026 filing $50K
  13. CAPITOL COUNSEL LLC Q1 2026 filing no amount stated

Federal contracts · USAspending.gov

Federal contracts

2 contract awards first obligated in the last 12 months to the company or a subsidiary it lists in its 10-K, $65K in total obligated as USAspending.gov lists each award when Lytir last read it. Largest first.

  1. Department of Veterans Affairs Apr 3, 2026 to MADRIGAL PHARMACEUTICALS, INC award $36K
  2. Department of Veterans Affairs Jun 5, 2026 to MADRIGAL PHARMACEUTICALS, INC award $30K

Sources: SEC EDGAR (Forms 4, 144 and 8-K), Senate LDA lobbying reports, USAspending.gov and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.